Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Titel:
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Auteur:
Miller, Vincent A Hirsh, Vera Cadranel, Jacques Chen, Yuh-Min Park, Keunchil Kim, Sang-We Zhou, Caicun Su, Wu-Chou Wang, Mengzhao Sun, Yan Heo, Dae Seog Crino, Lucio Tan, Eng-Huat Chao, Tsu-Yi Shahidi, Mehdi Cong, Xiuyu Julie Lorence, Robert M Yang, James Chih-Hsin